Carmel Murone

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

Andrew M. Scott, Fook-Thean Lee, Niall C. Tebbutt et al. · Proceedings of the National Academy of Sciences · 2007 · 217 citations · Full text

Immunology, Dermatology, Immunotherapy +16

Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

Timothy Price, Jennifer E. Hardingham, Chee Khoon Lee et al. · Journal of Clinical Oncology · 2011 · 209 citations · Full text

Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.

Lawrence Cher, Carmel Murone, Nathan Lawrentschuk et al. · PubMed · 2006 · 178 citations

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Rodney B. Luwor, Terrance G. Johns, Carmel Murone et al. · PubMed · 2001 · 173 citations

Tumor Xenografts, Gene Amplification, Immunology +17

Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.

Martin Cherk, Serene S. Foo, Aurora Poon et al. · PubMed · 2006 · 139 citations